Effect of Intracameral Injection of Preservative Free, Fixed Concentration of Combined Mydriatic plus Anaesthetic Formulation on Corneal Endothelial Cell Count in Phacoemulsification

Hosny M
{"title":"Effect of Intracameral Injection of Preservative Free, Fixed Concentration of Combined Mydriatic plus Anaesthetic Formulation on Corneal Endothelial Cell Count in Phacoemulsification","authors":"Hosny M","doi":"10.23880/oajo-16000208","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the efficacy and safety of intracameral injection of a standardized combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1% on corneal endothelial cell count at phacoemulsification. Methods: In this prospective randomized controlled study, 30 eyes of 30 patients undergoing phacoemulsification were assigned to 2 groups. 15 eyes (Intracameral Group A) received 0.2ml of a combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1% just after the first incision. While 15 eyes (Group B) received a topical regimen of one drop of each of cyclopentolate hydrochloride 1% and tropicamide 1%, every 15min for 1hour preoperatively. The main outcome measures were safety on corneal endothelium, by comparing the preoperative and 3 weeks postoperative corneal endothelium cell count in the two groups. Efficacy was also evaluated by measuring pupil size before capsulorhexis and before intraocular lens implantation, in both groups. Results: There was no significant statistical difference in the percentage of endothelial cell loss between the Groups A (27.4%) and the reference Group B (25.7%), with P value (0.595). Regarding Pupillary dilatation, adequate dilatation (>7.4mm) was achieved in both groups. Dilatation was maintained to the end of operation in the Fydrane group, while in the reference group, reduction in pupillary dilatation occurred in 20% (3 cases) reaching pupil diameter 5.5mm before IOL implantation. Conclusions: This study showed that intracameral injection of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1% is safe on corneal endothelium and effective in maintaining pupillary dilatation throughout the surgery","PeriodicalId":91939,"journal":{"name":"Open access journal of ophthalmology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open access journal of ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23880/oajo-16000208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Purpose: To evaluate the efficacy and safety of intracameral injection of a standardized combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1% on corneal endothelial cell count at phacoemulsification. Methods: In this prospective randomized controlled study, 30 eyes of 30 patients undergoing phacoemulsification were assigned to 2 groups. 15 eyes (Intracameral Group A) received 0.2ml of a combination of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1% just after the first incision. While 15 eyes (Group B) received a topical regimen of one drop of each of cyclopentolate hydrochloride 1% and tropicamide 1%, every 15min for 1hour preoperatively. The main outcome measures were safety on corneal endothelium, by comparing the preoperative and 3 weeks postoperative corneal endothelium cell count in the two groups. Efficacy was also evaluated by measuring pupil size before capsulorhexis and before intraocular lens implantation, in both groups. Results: There was no significant statistical difference in the percentage of endothelial cell loss between the Groups A (27.4%) and the reference Group B (25.7%), with P value (0.595). Regarding Pupillary dilatation, adequate dilatation (>7.4mm) was achieved in both groups. Dilatation was maintained to the end of operation in the Fydrane group, while in the reference group, reduction in pupillary dilatation occurred in 20% (3 cases) reaching pupil diameter 5.5mm before IOL implantation. Conclusions: This study showed that intracameral injection of tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1% is safe on corneal endothelium and effective in maintaining pupillary dilatation throughout the surgery
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
巩膜内注射不含防腐剂、固定浓度的麦散加麻醉联合制剂对超声乳化术中角膜内皮细胞计数的影响
目的:评价0.02%托品酰胺、0.31%苯肾上腺素、1%利多卡因标准联合注射对超声乳化术角膜内皮细胞计数的影响及安全性。方法:采用前瞻性随机对照研究,将30例超声乳化术患者30只眼分为两组。A组15只眼首次切开后给予0.02%托品酰胺、0.31%苯肾上腺素、1%利多卡因联合用药0.2ml。15只眼(B组)给予1%盐酸环戊酸酯和1%托品酰胺各1滴的局部治疗方案,每15min一次,持续1h。通过比较两组患者术前和术后3周角膜内皮细胞计数,主要观察角膜内皮的安全性。两组患者在撕囊前和人工晶状体植入术前测量瞳孔大小,评价疗效。结果:A组内皮细胞损失百分比(27.4%)与对照B组(25.7%)比较,差异无统计学意义,P值为0.595。在瞳孔扩张方面,两组均达到足够的瞳孔扩张(>7.4mm)。Fydrane组瞳孔扩张维持到手术结束,而参照组瞳孔扩张减少20%(3例),在人工晶状体植入术前瞳孔直径达到5.5mm。结论:本研究表明,眼内注射0.02%托品酰胺、0.31%苯肾上腺素和1%利多卡因对角膜内皮是安全的,且在整个手术过程中维持瞳孔扩张是有效的
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical Outcomes of Nd: YAG Laser Posterior Capsulotomy: Impact on Intraocular Pressure, Refraction, Anterior Chamber Depth, and Macular Thickness Psychological Wellbeing in Patients with Glaucoma: A Newer Perspective in Glaucoma Management Elevated Serum Hydrogen Sulfide in Age Related Macular Degeneration Modified Samuel Masket’s Technique Non-Surgical Pneumatic Repair of Stage 2 Macular Holes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1